Skip to content

PTSD Study

Evaluating the safety and effectiveness of a potential medication for PTSD

PTSD Study

We're seeking people with Post-Traumatic Stress Disorder (PTSD) to help us evaluate the safety and effectiveness of a potential new treatment.

PTSD is a psychiatric or mental health condition that may occur in people who have experienced or witnessed a terrifying, life-threatening or traumatic event. PTSD sufferers might experience flashbacks, nightmares or insomnia, and they might feel afraid and unsafe even though the danger or traumatic experience has passed. PTSD symptoms can last for many months and cause distress or problems in a person’s daily life, leading to social isolation and trouble communicating with others.

This study is investigating a new potential treatment to see if it can reduce symptoms for people with PTSD and improve quality of life. The study aims to evaluate whether the investigational treatment, HB-1, is safer, more tolerable and reduces PTSD symptoms compared to currently available medicinal treatments.

HB-1 is a combination of two medications that are approved in Australia for other illnesses/diseases but not for post-traumatic stress.

Who can take part?

You may be eligible to participate if you:

  • Are 18-65 years old
  • Have been diagnosed with post-traumatic stress disorder
  • Are medically stable on any current medication for at least two months
  • Can travel to SAHMRI for 4 study visits across a 3-month period
Check my eligibility

Why should I take part?

  • You will be contributing to important research that may help people with PTSD in the future
  • You may receive an active treatment that could improve your PTSD symptoms
  • You will speak to research staff regularly throughout the study to share your experiences and symptoms
  • Eligible participants will be reimbursed for travel-related costs

What does the study involve?

Eligible participants will be randomly assigned (like tossing a coin) to receive either the study medication or placebo. There is a 50% chance that you'll receive an active medication that could help control your PTSD symptoms and a 50% chance that you'll receive a placebo.

  • The study is double blinded, which means that neither you or us will know which treatment you receive.
  • If you decide to take part in the study, you will be required to participate for approximately 13 weeks. This includes a screening visits, twelve weeks of treatment and 1 week of follow-up. There will be 4 clinic visits in total.

Are you interested in taking part?

Check your eligibility
Aboriginal flag Torres Strait flag

SAHMRI is located on Kaurna Country. We pay respects to the Kaurna people of the Adelaide Plains and to all Aboriginal and Torres Strait Islander people. We are committed to embracing knowledge and culture as we continue our working journey to incorporate Aboriginal health research across all of our themes and further reconciliation.

Read more

"Tirki nguta tappa tangka marninithi"

(Learning and knowledge are the pathway to alter the mind)

- Uncle Lewis Yerloburka O’Brien, Kaurna Elder